The introduction of targeted therapies has dramatically changed the outcome for patients with oncogenedriven non-small cell lung cancer. Recent advances have led to the introduction of targeted therapies in early-stage non-small cell lung cancer, as well as the development of new strategies to overcome resistance. The current manuscript gives an update on targeted therapies in oncogene-driven non-small cell lung cancer.
(BELG J MED ONCOL 2024;18(7):253–257)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
